Lundbeck's goal to become carbon neutral by 2050 heavily leans on the global Paris Agreement, but the pharmaceutical companies plans to reach this target before then, says Lundbeck CEO Deborah Dunsire in the wake of the company presenting its new climate plan.
"We will probably be moving our own internal operations toward carbon neutrality within the 2034 time frame, but the difficult part will be helping the supply chain, where the majority of our carbon footprint lies, to work with us to become carbon neutral," says Dunsire, who, however, is sympathetic towards the notion that the 2050 net-zero emissions goal lacks ambition.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Biomarker Operations Lead 
Nordic Medical Affairs Manager 
Clinical Trial Administrator 
Senior Project Manager (GMP - Life Science) 
Industrial Designer- Design Engineer 
Clinical Trial Manager for development of in vitro diagnostics 
SAP System Specialist (Product Supply) – Business Application Services 
System Sales Development Consultant - Investment Projects, Merck Millipore 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Consultant Manager 
Communications Consultant 
Account Manager 
Production Director 
Key Account Manager, Europe and Asia 
IRT Manager, Clinical Drug Supply 
(Senior) Drug Substance Specialist 
Director Global Engineering 
Clinical Project Manager